FibroGen
Karen You have over 20 years of work experience, starting in 1997 with KPMG as an Audit Manager. Karen transferred to the San Francisco office after starting in Shanghai and worked with clients in various industries. In 2005, Karen joined OpenTV as an Assistant Controller and stayed there until 2010. From 2010 to 2015, they worked at LeapFrog as a Senior Manager, handling SEC reporting and technical accounting. Currently, Karen is employed at FibroGen, Inc. as a Senior Director, responsible for accounting, SEC reporting, and SOX compliance.
Karen You attended Shanghai Foreign Language School from 1987 to 1993. Karen then went on to study International Finance at Shanghai University of Finance and Economics, earning a B.A. degree from 1993 to 1997.
This person is not in the org chart
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.